ANI Pharmaceuticals acquires four NDAs from AstraZeneca for $46.5 Million
ANI Pharmaceuticals announced that it has acquired the NDAs and U.S. rights to market ATACAND, ATACAND HCT, ARIMIDEX, and CASODEX from AstraZeneca for $46.5 million in cash, royalties,…
Read More...
Read More...